The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation  

作　　者：Lin Ma Bowen Diao Zhaoqin Huang Bin Wang Jinming Yu Xiangjiao Meng 

机构地区：[1]Cheeloo College of Medicine,Shandong University,Jinan 250117,Shandong,P.R.China [2]Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,Shandong,P.R.China [3]Department of Gynecology,First Affiliated Hospital,School of Medicine,Shihezi University,Shihezi 832061,Xinjiang,P.R.China [4]Department of Radiology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250117,Shandong,P.R.China

出　　处：《Cancer Communications》2021年第12期1314-1330,共17页癌症通讯（英文）

基　　金：The study was funded by the National Natural Science Foundation of China(81972796 and 81972863);Radiation Oncology Innovate Unit,Chinese Academy of Medical Sciences(2019RU071);the Academic Promotion Program of Shandong First Medical University(2019ZL002);the Natural Science Foundation of Shandong(ZR2019MH010 and ZR2020MH289).

摘　　要：Over the past few years,immune checkpoint inhibitors(ICIs)have greatly improved the survival for patients with non-small cell lung cancer(NSCLC)without driver mutations.Compared with wild-type tumors,tumors with epidermal growth factor receptor(EGFR)mutations show more heterogeneity in the expression level of programmed cell death-ligand 1(PD-L1),tumor mutational burden(TMB),and other immune microenvironment characteristics.Whether ICIs are suitable for NSCLC patients with EGFR mutations is still worth exploring.In previous studies,no significantly improved benefits were observed with immunotherapy monotherapy in NSCLC patients with EGFR mutation.Here,we summarized and analyzed data from the clinical trials of ICIs or combined therapy in NSCLC patients with EGFR mutations.We also focused on the mechanisms affecting the efficacy of ICIs in NSCLC patients with EGFR mutations,the characteristics of potential responders,and provided insights into areas worth further investigations in future studies.

关 键 词：EFFICACY EGFR mutation immune checkpoint inhibitor non-small cell lung cancer tumor microenvironment 

分 类 号：R73[医药卫生—肿瘤]